NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, THE UNITED KINGDOM, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION, OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER ACTION BEYOND WHAT IS REQUIRED UNDER DANISH LAW.

Curasight A/S – Information document regarding the rights issue

29 April 2025

Information About The Issuer

Curasight A/S ("**Curasight**" or the "**Company**") is a Danish public limited liability company governed by Danish law including but not limited to the Danish Companies Act (DK. Selskabsloven). The Company was registered with the Danish Business Authority 22 May 2013. The Company's corporate registration number (CVR) is 35249389, and its Legal Entity Identifier (LEI) is 984500C9E3ADR98F1070. The address to the Company's website is: www.curasight.com.

Board of Directors' Responsibility Statement

The Board of Directors of Curasight is solely responsible for the content of this document. To the best of the Board's knowledge, the information provided herein is accurate and corresponds with the facts, and no information likely to affect its meaning has been omitted.

Competent Authority

This document is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended (the "**Prospectus Regulation**"). This document has been prepared in accordance with Article 1.4 (d) (b) of the Prospectus Regulation and structured in line with the requirements set out in Annex IX of the same regulation The Danish Financial Supervisory Authority (DK. Finanstilsynet), which is the competent authority in Denmark, has neither approved nor reviewed this document.

Each investor is encouraged to make their own assessment regarding the suitability of investing in the Company. Danish law governs this document, and the offer described herein. Any dispute arising from this document and related legal relationships shall be exclusively settled by Danish courts, with the Copenhagen City Court serving as the court of first instance.

Compliance with Reporting Obligations and Disclosed Information

The Board of Directors of Curasight hereby certifies that the Company has continuously complied with its reporting obligations and the obligation to disclose information throughout the entire period during which the Company's securities have been admitted to trading, including, where applicable, in accordance with Directive 2004/109/EC, Regulation (EU) No 596/2014, and, where applicable, Delegated Regulation (EU) 2017/565.

The Board confirms that, at the time of the offering, the Company is not postponing the disclosure of inside information pursuant to Regulation (EU) No 596/2014.

Mandatory information disclosed by the issuer, in accordance with its ongoing disclosure obligations, is available on the Company's website: www.curasight.com/investor/.

Background and Motive

On 4 April 2025, the Board of Directors of Curasight resolved on its intention to carry out an issue of DKK 100 million with preferential rights to Company's shareholders (the "**Rights**

Issue"). The issue was subject to approval at an extraordinary general meeting, authorizing the Board of Directors to carry out the Rights Issue and that the Board subsequently resolve to utilize the authorization to carry out the Rights Issue.

The Extraordinary General Meeting held on 23 April 2025 authorized the Board's to carry out the issue and the Board subsequently on 24 April 2025 resolved to carry out the Rights Issue.

Curasight A/S is the pioneer behind the novel imaging and therapeutic approach based on the urokinase-type plasminogen activator receptor (uPAR). The technology minimizes irradiation of healthy tissue by combining the targeted uTREAT® radiation therapy with the precise uTRACE® diagnostics. Several investigator-initiated phase II clinical trials have been completed or are currently undertaken. Curasight is currently running a phase II trial in prostate cancer as part of a global partnership with Curium - the world leader in radiopharmaceuticals. Furthermore, Curasight is actively generating clinical data using both uTRACE® and uTREAT® across a range of cancer types, including prostate cancer, bladder cancer, glioblastoma (brain cancer), neuroendocrine tumors (NET), head and neck cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer. Each of these indications represents unique development opportunities. Based on emerging clinical evidence, Curasight aims to identify and engage experienced partners for the later stages of development for uTRACE® and uTREAT®-as exemplified by the partnership with Curium for uTRACE® in prostate cancer.

Curasight strategically partners with highly specialised organisations to support its drug development efforts. This includes collaboration with leading Contract Research Organisations (CROs) and Contract Development and Manufacturing Organisations (CDMOs) that possess deep expertise in both diagnostic and therapeutic radiopharmaceuticals. Through these partnerships, Curasight ensures access to top-tier development and manufacturing capabilities, including the production of investigational medicines and the execution of clinical trials in full compliance with Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) standards.

According to Curasight's assessment, more capital is needed to finance operational advancements. Curasight is committed to developing its uTRACE® and uTREAT® platforms in parallel in a range of different cancers. The Rights Issue is executed to secure funding for the Company's R&D activities including maintaining the momentum of clinical trials being carried out under the partnership with Curium Inc. for uTRACE® in prostate cancer and initiate a phase I trial with uTREAT® in aggressive brain cancer besides activities to broaden the pipeline. For this reason, Curasight has decided to resolve on the Rights Issue.

Use of The Proceeds

Subject to the Rights Issue being fully subscribed, the Company will raise approximately DKK 100 million before deduction of issuance costs. If fully subscribed, the costs related to the Rights Issue are expected to amount to approximately DKK 8.1 million, of which around DKK 2.5 million constitutes cash compensation to guarantors. After deducting issuance costs, the net proceeds from the Rights Issue will amount to approximately DKK 91.9 million. The Company primarily intends to use the net proceeds to finance ongoing business activities, as outlined below.

- The last patient enrollment for Part II of the Phase II trial for uTRACE® (prostate cancer) with topline results in H2 2025 and final results in H1 2026.
- Completion of the Phase I trial for uTREAT® (brain cancer) with preliminary efficacy data in H2 2025 and final efficacy data in H1 2026.
- First patient included part II for uTREAT® (brain cancer) in H1 2026.
- Working capital.

The Board of Directors assesses that the net proceeds from a secured Rights Issue will be sufficient to finance the Company's operations to the end of 2025, covering the completion of the uTRACE® Phase

II trial (prostate cancer) including topline results, the uTREAT® Phase I trial (brain cancer) including preliminary efficacy data, and providing necessary working capital.

The Rights Issue is covered by subscription commitments and guarantee undertakings up to approximately 47.0 percent, corresponding to proceeds of approximately DKK 47 million before deduction of issuance costs. Neither the subscription commitments nor the guarantee undertakings are secured by bank guarantees, escrow funds, pledges, or similar arrangements. Consequently, there is a risk that one or more of the parties involved may be unable, in whole or in part, to fulfill their respective commitments.

Terms and Conditions

Event	Date
Last day of trading in shares including pre-emption rights	29 April, 2025
First day of trading in shares excluding pre-emption rights	30 April, 2025
Record date for participation in the Rights Issue	1 May, 2025
Trading in subscription rights on Spotlight Stock Market	30 April, 2025 – 14 May, 2025
Subscription period	2 May, 2025 – 16 May, 2025
Estimated date for announcement of the outcome of the Rights Issue (preliminary/final)	21 May, 2025
Settlement date	23 May, 2025
Estimated first day of trading in new shares on Spotlight Stock Market	06 June, 2025

Preferential Rights

Each holder of existing shares registered with Euronext Securities as of the record date, 1 May 2025, will be allocated forty-three (43) subscription rights (the "**Subscription Rights**") for each existing share held. Eighteen (18) Subscription Rights entitle the holder to subscribe for one (1) new share (the "**New Shares**").

Only whole numbers of new shares may be subscribed for (i.e., no fractions). Additionally, investors are offered the opportunity to apply for subscription of shares without preferential rights.

Trading in Subscription Rights

The Subscription Rights have been approved for admission to trading on Spotlight Stock Market Denmark. The Subscription Rights Trading Period commences 30 April 2025 at 9:00 a.m. CET and closes 14 May 2025 at 5:00 p.m. CET. The temporary ISIN code for the Subscription Rights is ISIN DK0063858774. Any of the Subscription Rights not exercised during the subscription period will lapse with no value, and the holder of such Subscription Rights will not be entitled to any compensation.

Dilution and Shareholding After the Rights Issue

Shareholders who choose not to participate in the Rights Issue may have their ownership diluted by up to approximately 70.5 percent of the total number of shares after the Rights Issue. However, they have the option to mitigate the financial impact of this dilution by selling their Subscription Rights.

Subscription Price
The New Shares are issued at a subscription price of DKK 1.98 per new share ("**The Subscription Price**").

Subscription of Shares
The subscription period for New Shares commences 2 May 2025 at 9:00 a.m. CET and closes on 16 May 2025 at 5:00 p.m. CET (the "**Subscription Period**"). Any Subscription Rights not exercised during the subscription period will lapse with no value, and the holder of such Subscription Rights will not be entitled to compensation. Once a holder of Subscription Rights has exercised such rights and subscribed for New Shares, such subscription cannot be withdrawn or modified by the holder.

Upon exercise of the Subscription Rights, the holder must pay an amount equal to the Subscription Price multiplied by the number of New Shares subscribed for. Payment for the New Shares shall be made in DKK and shall be made upon subscription against registration of the New Shares in the transferee's account with Euronext Securities no later than 23 May 2025, at 5:00 p.m. CET.

Holders of Subscription Rights shall adhere to the account agreement with their own Danish custodian institution or other financial intermediary, through which they hold existing shares.

Financial intermediaries through which a holder holds Subscription Rights may require payment on an earlier date.

Subscription for Remaining Shares
The general public and existing shareholders may apply to subscribe for any remaining shares not subscribed for by holders of Subscription Rights during the subscription period (the "**Remaining Shares**").

Remaining Shares are subscribed for at the same subscription price as shares subscribed through the exercise of Subscription Rights. Application to subscribe for Remaining Shares must be made using the subscription form available on the Company's website (www.curasight.com), or in accordance with account holder's own bank and its respective instruction. The subscription form must be submitted via the investor's own account-holding bank or financial intermediary, in accordance with their respective procedures and deadlines.

In case of oversubscription of Remaining Shares, allocation will be determined by the Board of Directors based on objective allocation criteria.

Payment for the allocated Remaining Shares is expected to be made on 23 May 2025 and will be settled through delivery versus payment (DvP) via the investor's own bank. The subscription amount will be withdrawn from the investor's account by the account-holding bank or broker.

Nominee-Registered Shareholders
Shareholders in Curasight whose holdings on the record date are nominee-registered must follow the subscription and payment instructions from their respective nominees.

Shareholders in Certain Ineligible Jurisdictions
Shareholders whose existing shares are directly registered in VP/service accounts with registered addresses in the United States, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore, Belarus or Russia, or any other jurisdiction where participation in the Rights Issue is not permitted will not be allowed to subscribe for new shares.

Interim shares

Shares subscribed for through the exercise of Subscription Rights will, upon payment and subscription, be issued as interim shares and registered in the investor's account with Euronext Securities (VP Securities A/S) under a temporary ISIN code: DK0063858691.

The interim shares will remain registered under the temporary ISIN until the completion of registration of the capital increase with the Danish Business Authority (DK. Erhvervsstyrelsen), at which point the interim shares will automatically be converted into ordinary shares under the ISIN code DK0061295797.

The interim shares will not be admitted to trading or official listing on Spotlight Stock Market. No separate VP notice will be issued in connection with the conversion of interim shares to ordinary shares.

Allocation of New Shares Subscribed for Without Subscription Rights

New Shares which have not been subscribed for by holders of Subscription Rights before the expiry of the subscription period may, without compensation to the holders of unexercised Subscription Rights, be subscribed for by existing shareholders and the general public, who have made binding undertakings to subscribe for such shares by use of the subscription form before the expiry of the subscription period. In case of oversubscription of the Remaining Shares in connection with binding undertakings, such Remaining Shares will be allocated according to allocation principles determined by the Board of Directors.

Listing of New Shares

The shares of Curasight are admitted to trading on Spotlight Stock Market. Trading in the New Shares is expected to commence on or around 06 June 2025, provided that registration with the Danish Business Authority has been completed.

Dividend Rights

The New Shares will, once registered with the Danish Business Authority, carry the same rights as the Company's existing shares, including rights to dividends and voting.

The New Shares will carry the right to dividends for the first time on the record date for dividends that occurs after the new shares have been registered in the share register maintained by Euronext and after the Rights Issue has been registered with the Danish Business Authority.

Information on the Processing of Personal Data

Personal data provided to Danske Bank or otherwise registered in connection with the preparation or administration of the Rights Issue is processed by Danske Bank, which is the data controller, for the purpose of administering and executing the Rights Issue. The processing of personal data is also carried out for Danske Bank to fulfill its legal obligations. For more information, please visit https://danskebank.se/privat/gdpr/privacy-notice.

Information About the Securities and Listing

The share in Curasight is listed on Spotlight Stock Market Denmark. The shares are traded under the ticker CURAS with the ISIN code DK0061295797. The ISIN code for the Subscription Rights is DK0063858774, and the ISIN code for the interim shares is DK0063858691. Trading in the New Shares is expected to commence around 06 June 2025, provided that registration with the Danish Business Authority has been completed.

Risk Factors

An investment in Curasight's securities involves various risks. The risk factors listed below are limited to those that Curasight considers essential and specific to Curasight and its securities. The risk factors presented below are based on the Company's assessment and the information available as of the date of publication of this document.

Clinical trials

The pharmaceutical industry in general and clinical trials in particular, are associated with great uncertainty and risks regarding delays and results in the studies. There is a risk that results from early clinical trials do not match results in more extensive clinical trials. There is a risk that the Company's current and planned future clinical trials will not indicate sufficient safety and efficacy in order for the Company to be able subsequently at a later date to out-license or sell the pharmaceutical projects according to plan. The most important study for Curasight at the moment is the phase II trial in prostate cancer with uTRACE®, where the first patient was enrolled and treated in June 2024. The study is covered by a partnership agreement with Curium Pharma, which will be responsible for production, distribution and commercialization when the product hopefully can be approved by the FDA in 2026/27. Furthermore, Curasight is in the process of initiating a phase I trial with uTREAT® for treatment in aggressive brain cancer (Glioblastoma), where the first patient is expected to be enrolled in H2 2025. This study is strategically important for the Company, as a positive outcome is considered to have great value for the Company within the treatment of several cancers. A negative outcome of the study will not be fatal for the Company, as the next generation of uTREAT® is already in the works, but it will delay a final approval of the product by the FDA by up to 12 months. If these risks materialize this may lead to a reduction of cash flows or a lack of cash flows for the Company and as a result the Company can incur losses.

Product Liability

Bearing in mind that the Company operates in the pharmaceutical industry, risks associated with product liability arise and are present. There is a risk that the Company will be held liable for an eventual event in clinical trials, even in cases where clinical trials are conducted by an external third party. In the event an incident does occur in a clinical trial and if the Company would be held liable for this, there is a risk that the Company's insurance coverage may not be sufficiently adequate to fully cover any future legal claims. There is a risk that this negatively affects the Company, both in terms of reputation as well as financially. A negative outcome or incident in connection with a clinical trial will always have a negative impact on the Company. In relation to the ongoing trial with uTRACE®, it is a well-tested product which has been tested in more than 400 patients in 9 cancers at Rigshospitalet - without a single incident or negative side effect being reported. If Curasight had to stop the ongoing trial as a result of an unexpected event (death or very strong side effects) - it could affect the Company negatively on cash flow and reputation, if the cause can be attributed to the product uTRACE®. The patient groups included in the clinical trials will already be diagnosed with cancer - with which there are two teams of physicians who follow the patients - those who run the current cancer treatment of the patient and those who run the clinical trial. There is thus great attention to the patient's well-being.

A company in clinical development phase

The Company was formed in 2013 and has since then been engaged in research and development of new drug candidates within cancer (imaging and therapy). The Company has not yet launched its specific PET imaging ligand uTRACE® or anti-cancer radiation treatment, uTREAT® to the market and therefore has not generated any revenues. The Board of Directors has made the assessment that further studies and clinical trials are required before the out-licensing or approval from the FDA and EMEA can be obtained. There is a risk that the Company will not be able to attract licensees or buyers within specific cancer indications. There is a risk that the Company will be adversely affected by a situation where it has minimal revenue, which may result in the need for acquisition of additional capital. If any of these risks materialize, it will have a significant impact on the Company's future prospects, including the inability to commercialize and sell its products, reduced or no earnings, ultimately leading to the Company having to cease its operations and file for bankruptcy.

Financing needs and capital

The Company's clinical studies with uTRACE® and uTREAT® currently underway and those planned for the future will entail significant costs for the Company. There is a risk that delays in clinical trials or product development will result in the cash flow being generated later than planned. Furthermore, there is a risk that the Company's targets will not be achieved within the timeframe determined and that it takes longer than planned to reach the milestones determined by the Board of Directors in the Company. A situation may arise where the Company may need to acquire additional capital in the future, depending upon how much revenue the Company is able to generate in relation to its expenses. There is a risk however that such additional capital may not be able to be acquired. If such risk materializes it may result in the development being temporarily halted or the Company being forced to conduct its business operations at a slower pace than desired, which can lead to delays or the commercialization not being implemented, and no revenue being obtained.

Registration and licensing at the agencies /governmental authorities

In order to be able to market and sell pharmaceutical drugs, authorisation must be obtained, and registration take place at the appropriate agency/governmental authority in their respective markets, such as the Food and Drug Administration (FDA) in the U.S. and the European Medicines Agency (EMA) in Europe. In the event the Company, directly or via collaborative partners, fails to obtain the requisite permits and registrations from the governmental authorities, there is a risk that the Company's ability to generate revenue will be inhibited. There is also a risk that observations and feedback on the Company's proposed plans for planned upcoming studies and clinical trials will result in delays and/or increased costs for the Company. The now in effect applicable rules and regulations, and their interpretations, may change. There is a risk that this will affect the Company's prerequisites for meeting regulatory requirements. There is thus a risk that the Company, directly or via its collaborative partners, will not receive the necessary permits and registrations with the governmental authorities. In the event that the Company does not receive the necessary permits and registrations from the governmental authorities there is a risk that the Company's earnings potential and financial position will be adversely affected The Company assesses the likelihood of the risk occurring as medium.

Development costs

The Company will continue to develop and further develop products within its area of business. It is not possible to predict the exact time and cost aspects of the development of the products in advance. This means that there is a risk that planned product development will be more costly than planned and budgeted. The company has a clear strategy to develop its two main products uTRACE® - for use in diagnostics and as a follow-up to ongoing treatment, as well as uTREAT® for targeted radiotherapy within cancers, all of which have a solid primary tumor. Since this is characterized as drug development, there is a clearly defined regime that must be followed, where we have detailed time and action plans within the phase division of the individual study. The biggest unknown factor in a study process is often the inclusion of patients in a study, where there is always a risk that the enrollment of patients will be slower than first assumed, the materialization of such risks will adversely affect the Company's business operations and earnings. If the development of a new product takes a longer period of time than projected, this may lead to increased development costs and thereby a reduced operating profit for the Company.

Key individuals and employees

The Company's key personnel consist of founders and personnel with several years of experience in the Company that have extensive and broad expertise. In the event of one or more key employees chooses to leave their employment with the Company, there is a risk that such a loss

for the Company could adverse consequences for its business operations and its potential earnings. If this risk materializes, the Company will need to recruit and hire personnel to replace key people, which may be a costly process, both in terms of time and money as the Company will likely incur increased expenses as a consequence of this. Curasight operates within nuclear medicine, which is a specialist area within cancer diagnosis and treatment. However, even though the area is growing rapidly as big pharma can see the value of this specialist area for diagnosing and treating cancer, which is why it will also be easier to recruit new employees, the lack of expertise is currently considered a material risk factor.

Additionally, there is also a risk that the Company will not be able to find a suitable replacement for the (former) employee. If the Company fails to find a replacement for a key employee, this will have significant implications for the Company's ability to develop and commercialize its products, potentially resulting in postponement, delays, which may result in a reduced or a lack of cash flow for the Company.

Unauthorised disclosure of information

There is a risk that the Company will be unable to protect itself against unauthorised disclosure of information, which could present a resulting risk that competitors may receive information about, take advantage of and benefit from, the know-how that has been developed by the Company. The Company's employees and individuals associated with the Company are subject to confidentiality and non-disclosure obligations, however there is a risk that via the use of such unauthorised disclosure of information, the Company's competitors will further develop their products and thereby that the Company faces increased competition, which may adversely affect the Company's business operations, financial position, and earnings.

Competitors

The Company's potential future competitors are multinational companies with significant financial resources. There is a risk that substantial investment and product development by a competitor will result in a less favourable situation in terms of sales or revenue opportunities, due to the possibility a competitor may develop products that outperform the Company's products, thereby taking market share from the Company. Furthermore, companies with global operations currently working within similar adjacent fields could decide to establish themselves within the same business area as the Company's business area. The materialization of such risks may lead to increased competition which can have negative impacts on the sales prospects and profit prospects for the Company in the event competitors develop products with better function and/or better quality.

Additionally, there is a risk that parties with competing business operations obtain patents in fields related or adjacent to the Company's existing patents or patent applications, resulting in the competitors' treatment alternatives attaining the same efficacy as that of the Company's alternatives. Risk is present that as a result, the Company will be faced with a more difficult marketing situation with an increasingly competitive situation, which may adversely affect the Company's revenue and earnings.

Suppliers/Manufacturers

The Company has a working relationship with suppliers and manufacturers. If one or more of the Company's suppliers or manufacturers choose to cease their cooperative efforts with the Company, there is a risk that this will adversely affect the activities relating to the development of the drug or future sales and/or earnings. There is also the risk that the Company's suppliers and/or manufacturers do not satisfy the quality standards, which the Company has established. There is a risk that the establishment of relationships with new suppliers or manufacturers will

be more costly and/or take longer than the Company calculates. In the event of a suspension or the ending of the working relationship with a supplier or manufacturer, there is a risk that the Company will need to spend resources on establishing new working partnerships. Such a process may become costly and as a result the Company's operating profit will decrease. There are currently a handful of suppliers who can produce and distribute Curasight's products. As the nuclear medicine market grows the Company have noted that new suppliers are emerging within this area and will with time intensify the competition among suppliers. Curasight always strives to have a back-up supplier, so that the negative effect is limited if a supplier suddenly cannot deliver an isotope or similar. If the Company cannot replace a supplier who has terminated its agreement with the Company, it may result in a reduced or a lack of cash flow for the Company. As such, if the Company cannot find other suitable supplies or manufacturers, this may adversely impact the prospects of the Company.

Foreign exchange risk

A portion of the Company's future sales revenues may be received, and costs may be incurred, in various currencies other than DKK, including USD. Exchange rates can change substantially. There is a risk that the Company's costs and future revenues are adversely impacted by fluctuations in exchange rates. If, for instance, the Danish krone DKK (which is the Company's accounting currency), increases in value, there is a risk that the Company's future exports will decrease. This, in turn, will lead to a decrease in revenue for the Company and reduced operating profits for the Company.

Political risk

The Company operates in a number of different countries, and in a number of various ways. There is a risk that changes in laws, income taxes, customs duties, exchange rates and other conditions for foreign companies will adversely affect the Company's business operations. The Company is also affected by political and economic uncertainties in these countries. Furthermore, certain products from Curasight are subject to regulatory approval by governmental bodies. Medicines must be approved before they can be sold in Denmark, the EU or the US. The company must apply to either the Danish Medicines Agency or the EMA (EU) for approval of medicinal products in the EU. The application must contain documentation of the medicinal product's effect. There is a risk that the Company will be adversely affected by possible domestic political or governmental bodies' decisions. Should such risks materialize, the Company may face negative consequences in terms of the Company's business activities and its earnings potential.

Insurance risk

The Company has business insurance, which includes property damage and business interruption loss, legal liability, and product liability coverage, as well as general liability insurance. Patients who participate in Curasight's trials may be subject to side effects and there is a risk that the Company will suffer injury or loss, or incur a liability for compensation for damages, which is not covered or only partially covered by the insurance, in which event this may adversely affect the Company's business operations, earnings and financial position. This poses the risk that in such scenario, the Company will have to pay damages or repairs via its own financial resources, which results in a deteriorating financial position for the Company.

Patent Risk

The Company has obtained patents and other intellectual property rights and applied for further patents. Patents and intellectual property rights always have a limited service life, and the Company strategy is to continuously secure rights to new inventions and optimize the patent portfolio around the Company technology. No Company IP have been conflicted by third parties, but in the event that the Company is required to defend its patent rights against a competitor, there is a risk that this will result in significant costs being incurred, which may adversely affect

the Company's business operations, earnings and financial position.

There are no identified issues related to other parties' patent rights which may limit the ability or possibilities for one or more of the Company's future collaborative partners to freely use the affected product or production method. However, it is not possible to anticipate the outcome of any future potential patent rights or disputes in advance. To the Company´s best knowledge, there is a low risk of conflicts which can result in potential litigation relating to intellectual property rights. The costs of any such potential conflicts, even in the event of a final result with a favourable outcome for the Company, can be substantial. There is always a risk that unforeseen conflicts could negatively impact the Company's earnings and financial position, or lead to difficulties or delays in commercializing future products, thereby affecting revenue generation. This risk also applies to other intellectual property rights, such as brands and trademarks.

Disputes and legal claims

There is a risk that the Company will be involved in disputes within the framework of its ordinary business activities and may also be subject to claims concerning contractual issues, product liability and alleged problems or mistakes in deliveries of the Company's products. For example, disputes may arise with Curasight's collaborative partners in connection with clinical trials. There is a risk that such disputes and claims will be time-consuming for the Company to deal with, disturbing normal business operations, and eventually result in the incurring of significant costs. It is not possible to anticipate in advance the outcome of complex disputes, and there is thus a risk that disputes will have a material adverse impact on the company's business operations, earnings, and financial position.

The Company may raise additional capital

The Company may need to finance its operations in the future by raising additional capital. Such financing initiatives could be carried out either by issuing additional shares or other financial instruments in the Company, or through bank loans or other forms of credit. The availability of new capital may be affected by disruptions in the capital and credit markets, while borrowing could negatively impact the Company's debt ratio. The need for additional capital will increase if costs are higher than expected for obtaining regulatory approvals for Curasight's products. The ability to raise additional capital depends on financial, economic, and other factors, many of which are beyond the Company's control. If the Company fails to secure additional financing on acceptable terms when needed, it may need to adjust its business plan and reduce its development activities, which could have negative consequences for the Company's results.

Risk of dilution in future share issues

Curasight may require additional capital to finance its operations. The company might need to make investments related to continued research and development, expansion, product development, and obtaining new regulatory approvals, which could necessitate raising additional funds. This could be done through the issuance of shares, share-related instruments, or debt securities. There is a risk that such additional financing may not be available to the company on acceptable terms when needed, or it may not be available at all. Furthermore, any potential new share issues would dilute the ownership of shareholders who, for any reason, are unable or choose not to participate. The same applies if the share issue is directed to parties other than the existing shareholders.